Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pinwheel Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, BORI, IBRAHIM D. The portfolio's activity is currently limited to 1 distinct art unit. This indicates that the company's current efforts to secure patent rights are focused on 1 technical disclosure within the biotechnology field.
BORI, IBRAHIM D is the busiest examiner, responsible for 1 pending office action. This 1 examiner and 1 art unit account for the entire current pending workload for the company's portfolio. For a practitioner, this means that the prosecution process is centralized. The outcome of the company's current intellectual property efforts depends on navigating the specific requirements of 1 art unit and the individual review style of BORI, IBRAHIM D.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541391 | ANTICOAGULANT REVERSAL AGENTS | BORI, IBRAHIM D | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18541391 | ANTICOAGULANT REVERSAL AGENTS | BORI, IBRAHIM D | 1629 | §112Other | Non-Final OA | 2d overdue | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial